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Summary
Since the discoveries of a putative AIDS virus in 1984 and of millions of asymptomatic carriers 
in subsequent years, no general AIDS epidemic has occurred by 2011. In 2008, however, it has 
been proposed that between 2000 and 2005 the new AIDS virus, now called HIV, had killed 1.8 
million South Africans at a steady rate of 300,000 per year and that anti-HIV drugs could have 
saved 330,000 of those. Here we investigate these claims in view of the paradoxes that HIV 
would cause a general epidemic in Africa but not in other continents, and a steady rather than 
a classical bell-shaped epidemic like all other new pathogenic viruses. Surprisingly, we found 
that South Africa attributed only about 10,000 deaths per year to HIV between 2000 and 2005 
and that the South African population had increased by 3 million between 2000 and 2005 at a 
steady rate of 500,000 per year. This gain was part of a monotonic growth trajectory spanning 
from 29 million in 1980 to 49 million in 2008. During the same time Uganda increased from 12 
to 31 million, and Sub-Saharan Africa as a whole doubled from 400 to 800 million, despite high 
prevalence HIV. We deduce from this demographic evidence that HIV is not a new killer virus. 
Based on a review of the known toxicities of antiretroviral drugs we like to draw the attention 
RIVFLHQWLVWVZKRZRUNLQEDVLFDQGFOLQLFDOPHGLFDOÀHOGVLQFOXGLQJHPEU\RORJLVWVWRWKHQHHG
RIUHWKLQNLQJWKHULVNDQGEHQHÀWEDODQFHRIDQWLUHWURYLUDOGUXJVIRUSUHJQDQWZRPHQQHZERUQ
babies and all others who carry antibodies against HIV.
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1. Introduction
In 1984 the hypothesis was advanced in the US that a new AIDS virus was at 
WKH WKUHVKROGRI FDXVLQJDQHSLGHPLFRI LPPXQRGHÀFLHQF\ DOLDV$,'6 LQ OLQHZLWK
the classic germ theory of disease (Gallo et al., 1984; Altman L.K., newspaper arti-
cle in the New York Times, New York, pp. C1-C3, April 24, 1984). This virus-AIDS 
hypothesis has since monopolized AIDS research and the treatment and prevention 
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of AIDS, although the predicted general epidemic never showed up. In view of this 
we have re-analyzed the epidemiology of AIDS and HIV, particularly of Africa, which 
LVUHSRUWHGO\PRVWDͿHFWHG:HKDYHWKHQFRPSDUHGRXUÀQGLQJVZLWKWKHSUHGLFWLRQV
made by the classic germ theory of disease.
The germ theory of disease predicts that a new (relative to a population) patho-
genic virus or microbe causes an exponentially spreading epidemic of new microbe-
VSHFLÀF LOOQHVVHV DQG GHDWKV ZLWKLQ ZHHNV WR PRQWKV DIWHU WKH DUULYDO RI WKH QHZ
pathogen (Encyclopædia Britannica, 2010). These fast kinetics are the results of the 
short generation times of microbes. Bacteria double in only 30 minutes; and human 
and animal viruses multiply 100- to 1000-fold within 8 to 24 hours (Fenner et al., 1974; 
Freeman, 1979; Mims and White, 1984). Since each carrier can infect numerous others, 
infections spread exponentially like biological chain reactions and run until all suscep-
tible subjects are either killed or have acquired immunity, which limits such epidemics 
typically to a few months (Fenner et al., 1974; Freeman, 1979; Mims and White, 1984; 
Duesberg, 1991, 1994, 1996). The resulting bell-shaped epidemiological curves of ill-
QHVVHVDQGGHDWKVZHUHÀUVWGHVFULEHGIRUDSODJXHLQ/RQGRQLQWKDWODVWHGVHY-
eral months (Institute of Historical Research, 1990). Many other bell-shaped epidemics 
KDYHVLQFHWKHQEHHQGHVFULEHGDVIRUH[DPSOHWKHJOREDOÁXRIVKRZQLQ)LJ
and the polio epidemics of the 1950s, which all lasted 2-3 months.
In view of the widespread fear of a general AIDS epidemic following the 
announcement of an AIDS virus in 1984, the National Academy of Sciences and the 
Institute of Medicine appointed a blue ribbon committee of experts to confront the 
Figure 1 – Bell-shaped curves of the mortality of Americans and Europeans during the global Flu epidemic 
of 1918. As predicted by the germ theory of disease, the Flu-epidemic increased mortality exponentially over 
4 weeks about 6-fold. It then declined exponentially to normal mortality over 4-6 weeks. The picture is from 
http://health.mo.gov/training/epi/Pandemic.html. Accessed February 4th, 2011.
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expected AIDS epidemic (Institute of Medicine, National Academy of Sciences, 1986). 
In the light of the classic germ theory of disease this committee predicted in 1986, in 
a volume termed Confronting AIDS, a fast spreading AIDS epidemic that would deci-
mate the general American population based on sexual and perinatal transmission of 
HIV: “There are 1 to 1.5 million Americans currently infected with HIV. Of these, 20 
to 30 percent are expected to develop AIDS by 1991. AIDS cases … acquired through 
heterosexual contact will increase from 1100 in 1986 to almost 7000 in 1991… Pediat-
ric AIDS cases will increase almost 10-fold during the next 5 years to more than 3000 
cumulative cases …” (Institute of Medicine, National Academy of Sciences, 1986).
But despite these predictions, the American AIDS epidemic has remained restrict-
ed to non-general risk groups from its beginnings in the early 1980s (Duesberg, 1989) 
until now. By 2008 the cumulative total were 513,138 male homosexuals, who had 
used multiple recreational drugs, 341,546 intravenous drug users, 188,585 “heterosex-
uals … at high risk for HIV infection” (typically drug addicted), 20,509 hemophiliacs, 
other transfusion recipients and babies born to mothers from HIV risk groups (Dues-
berg et al., 2003; Centers for Disease Control, 2008). According to the AIDS statistics 
from the Centers for Disease Control (CDC) the American epidemic has increased 
in these risk groups slowly but not exponentially from 1984 until 1993, and then 
GHFUHDVHGVORZO\XQWLO2QFHWKHYDULRXV$,'6GHÀQLWLRQVDQGWHVWLQJPHWKRGV
Figure 2 – Statistics of the American AIDS epidemic from the U.S. Centers of Disease Control. “This slide 
presents trends from 1985 through 2008 in the estimated numbers of AIDS diagnoses and deaths of adults 
and adolescents (aged 13 years and older) with AIDS, in the 50 states, the District of Columbia, and the U.S. 
dependent areas. The peak in AIDS diagnoses during 1993 can be associated with the expansion of the AIDS 
surveillance case de!nition implemented in January 1993.” (Centers for Disease Control, 2011). Note: A new 
viral epidemic would have risen and declined exponentially within weeks or months after its discovery in 
1984, as shown above for the 1918 Flu epidemic in Fig. 1. Instead the American AIDS epidemic increased 
slowly, not exponentially over 7 years, then declined slowly over 4 years and since then has remained steady 
for over 12 years now – much like a chemical lifestyle epidemic (Duesberg et al., 2003).
Figure 
2. 
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had become steady in 1997, the AIDS epidemic had also become steady until now, 
13 years later (Fig. 2), (Centers for Disease Control, 2011). Slowly rising, declining or 
steady epidemics are, however, the characteristic patterns of chemical lifestyle diseas-
HVQRW WKDWRIDQHZYLUDOHSLGHPLF 'XHVEHUJHWDO$OPRVW LGHQWLFDOÀJXUHV
have been reported recently for Italy, where AIDS is also still restricted to the original 
risk groups and paediatric AIDS is virtually non-existent (Ruggiero et al., 2009).
Soon after the appearance of Confronting AIDS, Anderson et al. (1988) predicted 
in Nature, based on “mathematical models of the transmission dynamics of HIV”, 
that in “developing countries” “AIDS is capable of changing population growth rates 
from positive to negative values over time scales of a few decades”. And in 2000 
“over 5000 scientists” signed the Durban Declaration, which projected that 24 mil-
lion HIV-positive Africans are “likely to die within 5 years” (The Durban Declaration, 
2000). But despite over 30 million of HIV antibody-positive people worldwide (The 
'XUEDQ'HFODUDWLRQQRJHQHUDO HSLGHPLFRI LPPXQRGHÀFLHQF\ZDV UHFRUGHG
(Baumann et al., 1995; Stewart et al., 2000; Duesberg et al., 2003; Bauer, 2007).
Recently, however, a new study by Chigwedere et al. from Harvard University 
“estimated” that from 2000 to 2005 1.8 million South Africans were killed by HIV at a 
steady rate of 300,000 per year (Chigwedere et al., 2008). These estimates were based 
on information from the World Health Organization (WHO) (World Health Organiza-
tion, UNAIDS, UNICEF, 2008a). Chigwedere et al. (2008) further claimed, based on 
“modeling” the South African epidemic, that anti-HIV drugs could have prevented at 
least 330,000 of those 1.8 million estimated deaths.
Since no general HIV-AIDS-epidemics had been observed in any other continent, 
despite millions of HIV antibody-positives, and since steady losses of lives per year for 
6 years are inconsistent with the exponential increases and declines of new germ epi-
demics, we have investigated here the evidence for the claim that HIV killed 1.8 million 
South Africans at 300,000 per year from 2000 to 2005. In view of the inherent toxicities of 
DQWL+,9GUXJVVHH6HFWLRQEHORZZHIXUWKHUDVNHGZKHWKHUWKHSRWHQWLDOEHQHÀWVRI
these drugs, claimed by the Harvard study, do indeed outweigh their inherent toxicities. 
This issue is of interest also for embryologists, who are called to evaluate the 
SRWHQWLDODQGDFWXDOHͿHFWVRIDQWLUHWURYLUDOGUXJVRQGHYHORSLQJKXPDQVGXULQJSUH-
natal life and in babyhood.
2. Population of South Africa grows steadily, despite claims of huge losses from a 
new epidemic of HIV
To answer our question about the reportedly huge losses of South African lives 
from HIV, we checked three sources:
1) The WHO;
2) The AIDS-mortality statistics of South Africa;
3) The population statistics of South Africa for new, abnormal losses between 2000 
and 2005.
1) WHO statistics. Surprisingly, the WHO/UNAIDS does not list any numbers 
on “Reported HIV cases” and “Reported AIDS cases” in their epidemiological “Fact 
Sheet” for South Africa for the period of 2000 to 2005 (World Health Organization, 
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UNAIDS, UNICEF, 2008b). As shown in Fig. 3, the respective statistics from 1996 
until 2007 are two empty boxes (World Health Organization, UNAIDS, UNICEF, 
E7KXVZHFRXOGQRWFRQÀUPWKH+,9$,'6HSLGHPLFGHVFULEHGE\&KLJZHGHUH
et al. (2008) based on the sources they cited.
$,'6PRUWDOLW\RI6RXWK$IULFDIURPWR,QDQHͿRUWWRÀQGLQGHSHQG-
ent evidence on this issue, we investigated the AIDS mortality statistics of South Afri-
ca. Unexpectedly, we found that Statistics South Africa attributed an average of only 
10,000 deaths to HIV per year between 2000 and 2005 (Tab. 1) (Statistics South Africa, 
2007; Statistics South Africa, 2008). This is 30-times less than Chigwedere et al. (2008) 
claimed. And even this relatively low number may be an over-estimate, because the 
27 “HIV-diseases” that are part of the AIDSyndrome (Centers for Disease Control, 
1992) include the most common South African diseases and causes of death, namely 
“tuberculosis, pneumonias and intestinal infections” listed as “HIV-diseases” by Sta-
tistics South Africa (Statistics South Africa, 2007). Thus common African diseases may 
have been erroneously attributed to HIV, because they coincided with a positive test 
IRU DQWLERGLHV DJDLQVW+,9:H FRQFOXGH WKDW WKHUH LV QR YHULÀDEOH HYLGHQFH WKDW D
putative HIV-epidemic killed 300,000 South Africans per year between 2000 and 2005, 
as claimed by Chigwedere et al. (2008).
3RSXODWLRQVWDWLVWLFVRI6RXWK$IULFD ,QDQHͿRUW WRREWDLQIXUWKHU LQGHSHQGHQW
evidence for HIV-dependent life losses, we looked for a corresponding decline in the 
population growth trajectory of South Africa. Unexpectedly we found that the popu-
lation of South Africa had increased by 3 million from 2000 to 2005, based on con-
cordant statistics from South Africa and the US Census Bureau (Statistics South Africa, 
2007; US Census Bureau, International Data Base, 2008). As shown in Tab. 1 and Fig. 
4A, this gain extended a steady growth trajectory of South Africa from 29 million in 
1980 to 47.5 million in 2005, which then continued at the same steady rate (Statistics 
Figure 3 – Absence of numbers from “Reported HIV cases” and “Reported AIDS cases” in the WHO statistics of 
South Africa (World Health Organization, UNAIDS, UNICEF, 2008b).
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South Africa, 2000; Statistics South Africa 2007; US Census Bureau, International Data 
Base, 2008). The change of the growth trajectory predicted by the losses of 300,000 per 
year for 6 years is shown as a hypothetical branch of the observed monotonic growth 
curve in Fig. 3A. But the actual growth curve did not show any evidence for such loss-
es. In sum, the South African population grew steadily during the period from 2000-
2005, extending a long-established growth trajectory. Indeed, this growth curve has 
Table 1 – Population statistics of South Africa from 1980 until 2008.















1990 38,500  0.7
1991 39,300  1.7
1992 40,100  2.2
1993 40,900  4.0
1994 41,600  7.6
1995 42,200 10.4
1996 42,800 14.4
1997 43,300 17.0 *
1998 43,900 22.8 *
1999 44,500 22.4 10.0
2000 45,100 24.5 10.5
2001 45,600 24.8 *
2002 46,100 26.5 *
2003 46,600 27.9 *
2004 47,000 29.5 13.0




(a) Statistics South Africa and US Census Bureau (Statistics South Africa, 2007; Statistics South Africa, 2000; 
US Census Bureau, International Data Base, 2008).
(b) National Department of Health South Africa (National Department of Health South Africa, 2007).
(c) Statistics South Africa (Statistics South Africa, 2007; Statistics South Africa, 2008) Statistics South Africa. Mor-
tality and causes of death in South Africa, 2006:  Findings from death noti!cation. Statistics South Africa, 2008.
*Not reported because HIV-deaths were below 10th rank.
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been so consistently monotonic that it predicted exactly the increase of the South Afri-
can population by 3 million between 2000 and 2005 (see Tab. 1, Fig. 4A). 
Moreover, a new viral epidemic causing steady losses of 300,000 per year for 6 
years is not compatible with the classic germ theory of disease. Instead, the germ the-
ory predicts that new viruses and microbes cause epidemics that rise exponentially, 
because of exponential growth and spread of microbes, and then fall exponentially, 
because of the resulting immunity and deaths within several months, rather than go 
steady over 6 years (see Fig. 1 and Introduction). HIV has been demonstrated 20 years 
ago to induce anti-viral immunity - but not AIDS - within several weeks after infection 
(Clark et al, 1991; Daar et al, 1991), just like any other virus (Duesberg, 1989). Thus a 
new virus could have been a plausible explanation for a seasonal epidemic of several 
months within a given year, but not for a steady loss of lives for 6 years in a row.
In sum, neither the WHO, nor the mortality statistics of South Africa, nor the popula-
WLRQVWDWLVWLFVRI6RXWK$IULFDSURYLGHYHULÀDEOHHYLGHQFHIRUWKHSUHGLFWHGHSLGHPLRORJL-
cal pattern associated with a new killing virus in South Africa between 2000 and 2005. 
Figure 4 – (A) The population growth curve of South Africa from 1980 until 2007 based on Statistics South Afri-
ca and the US Census Bureau (Statistics South Africa, 2000, 2007; US Census Bureau, International Data Base, 
2008). A hypothetical branch of the growth curve shows the expected population growth curve if a new AIDS 
epidemic had claimed 300,000 lives per year from 2000 to 2005. (B) The percentage of HIV-antibody-positive 
South Africans is based on data from antenatal clinics of the South African Department of Health (Depart-
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Similar non-correlations between mortality and prevalence of HIV were found in 
Italy. The Italian case is, however, based on actual data rather than on estimates (Rug-
giero et al., 2009).
7KH GLVFUHSDQFLHV EHWZHHQ RXU ÀQGLQJV DQG WKH FODLPV E\ &KLJZHGHUH HW DO
 PLJKW EH GXH WR XQYHULÀDEOH LQIRUPDWLRQ IURP WKH:+2 RQ ZKLFK WKRVH
authors relied. Skepticism about AIDS statistics from the WHO has been voiced 
by the recent Chief of the Global Programme on AIDS of the WHO, Public Health 
professor James Chin from the University of California at Berkeley, who wrote that 
“AIDS programs developed by international agencies and faith based on organiza-
tions have been and continue to be more socially, politically, and moralistically cor-
rect than epidemiologically accurate.” (Chin, 2007). Since Chin also was a member of 
the ‘Confronting AIDS’ committee of the National Academy and the Institute of Med-
icine in 1986 (Institute of Medicine, National Academy of Sciences, 1986), his remarks 
cannot be dismissed lightly. More recently the WHO has also been accused of manip-
XODWLQJHSLGHPLRORJLFDOQXPEHUVRIDQHZÁXHSLGHPLF&RKHQDQG&DUWHU
To test our hypothesis that HIV may not be pathogenic, we asked next, whether 
the population growths of other HIV antibody-positive African countries were also 
independent of HIV, as for example Uganda. 
3. Population of Uganda doubles despite HIV epidemic
Based on the AIDS literature, Uganda is the epicenter of the African AIDS epidem-
ic and thus a primary challenge of hypotheses on the pathogenicity of HIV. In 1989 
the Minister of Health has already announced that 5.8% of the population was HIV 
antibody-positive (Goodgame, 1990). It is for this reason that the New England Jour-
nal of Medicine described Uganda as a model for emerging AIDS epidemics in Africa: 
“AIDS is already the most common cause of admission and death among hospitalized 
adults” (Goodgame, 1990). Concordantly Mulder et al. claimed in 1994 in The Lancet 
and in Aids that, “Among adults, half of all deaths and among those aged 13-44 over 


















Figure 5 – (A) The population growth curve of Uganda from 1980 until 2008 based on statistics from the 
US Census Bureau (US Census Bureau, International Data Base, 2008). (B) The percentage of HIV-antibody-
positive Ugandans is based on data from the Ugandan Minister of Health (Goodgame, 1990) and the World 
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In contrast to these daunting prognoses the Ugandan population was growing rapid-
ly, much as that of South Africa (Fiala, 2009). Vital statistics from the US Census Bureau, 
International Data Base (2008) show that the Ugandan population has increased 2.5-fold 
 IURP WRPLOOLRQVLQFH WKHHDUO\VZKHQ+,9SUHVXPDEO\ÀUVWDSSHDUHG LQ
Africa (Goodgame, 1990; Mulder et al., 1994b); see Fig. 5A and Tab. 2. 
Based on statistics from the World Health Organization, UNAIDS, UNICEF 
(2008a) the 5.8% HIV-prevalence of Ugandans in 1989 shot up to about 13% in 1990 
and then slowly declined spontaneously back to about 5% again by 2006 and 2007 
(Fig. 5B). Since the WHO “fact sheets” again lacked any numbers of “Reported HIV 
cases” from Uganda (World Health Organization, UNAIDS, UNICEF, 2008a), it is 
unclear whether, and if so, why HIV would have decreased in Uganda during the 
same time, in which it increased in South Africa (see Section 5).
The fact that the population of Uganda increased 2.5-fold during the HIV-AIDS 
era, although it was described in the professional literature as model for the dire con-
sequences of a fatal HIV epidemic, lends support to our conclusion that South Afri-
can population growth is also independent of HIV. 
4. Population of total Sub-Saharan Africa doubles from 400 to 800 million 
between 1980 and 2007 
,Q DQ HͿRUW WR UDLVH RXU LQYHVWLJDWLRQ DERYHYDULDWLRQV DPRQJSRSXODWLRQ VWDWLVWLFV
DQG$,'6HSLGHPLFVRIGLͿHUHQW$IULFDQFRXQWULHVZHDVNHGQH[WZKHWKHU WKHSRSXOD-
tion of Sub-Saharan Africa as a whole was increasing or decreasing – in the face of the 
widespread prevalence of antibodies against HIV (Quinn et al., 1986; Goodgame, 1990; 
Merson, 1993; Mulder et al., 1994b; The Durban Declaration, 2000; Gisselquist et al., 2002). 
Again we found in the statistics of the World Bank that the population of Sub-
Saharan Africa as a whole had doubled during the HIV-AIDS era, from almost 400 
million in 1980 to about 800 million in 2007 (World Bank, 2008). On May 4, 2011, the 
New York Times reported that Africa had just reached 1 billion and is projected to 
be the fastest growing continent for the coming century. The article remarked “that 
the AIDS epidemic, devastating as it has been, has not been the demographic disas-
ter that was once predicted.” (Gillis J, Dugger C., newspaper article in the New York 
Times, New York, p. A1, A3, May 4, 2011).
We conclude that the predicted epidemiological patterns associated with a wide-
VSUHDG QHZ NLOOLQJ YLUXV QHYHU VKRZHG XS LQ$IULFD ,Q WKH IROORZLQJ ZH EULHÁ\
investigate the theory that HIV is a passenger virus.
5. Could HIV be a passenger virus?
%\GHÀQLWLRQDSDVVHQJHUYLUXV LVQRWVX΀FLHQWDQGQRWQHFHVVDU\WRFDXVHDGLV-
ease (Duesberg, 1994). A passenger virus can thus be associated with healthy people 
DQG DOVRZLWK SHRSOH VXͿHULQJ IURPYLUXVLQGHSHQGHQW GLVHDVHV+XPDQ H[DPSOHV
are cytomegalovirus, adenovirus or reovirus (Fenner et al., 1974; Fields, 2001).
The hypothesis that HIV is a passenger predicts that its spread and prevalence do 
QRW FRLQFLGHZLWKPRUWDOLW\7R WHVW WKLVSUHGLFWLRQZH LQYHVWLJDWHG WKH HͿHFW RI WKH
spread and prevalence of HIV on the population growth curve of South Africa.
82 Peter H. Duesberg, Daniele Mandrioli, Amanda McCormack, et al.
For this purpose we plotted the HIV-antibody prevalence of the South African popula-
tion reported by the National Department of Health South Africa since 1990 (Department 
of Health South Africa, 2007) on a separate panel of Fig. 4, which shows the population 
JURZWKFXUYHRI6RXWK$IULFD)LJ%VKRZVWKDWDQWL+,9DQWLERGLHVZHUHÀUVWGHWHFWHG
in 1990 in 0.7% of the population. This percentage then increased gradually (not exponen-
WLDOO\RYHUDERXW\HDUVXQWLOZKHQLWOHYHOHGRͿEHWZHHQDQG
By comparing Fig. 4A and B it can be seen that the steady growth trajectory of the 
$IULFDQSRSXODWLRQ VLQFH  LV XQDͿHFWHGE\ WKH ULVH RI WKH+,9SUHYDOHQFH IURP
0.7 to 30% between 1990 and 2000 and the steady prevalence of HIV since then. Inde-
Table 2 – Population statistics of Uganda from 1980 to 2008.






























(a) US Census Bureau (US Census Bureau, International Data Base, 2008). 
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pendence of the growth trajectory of the South African population of HIV prevalence 
is in agreement with the hypothesis that HIV is a passenger virus. Moreover, the rise 
of the HIV-antibody prevalence from 0.7% in 1990 to about 30% in 2000 is much too 
slow for the natural, exponential spread of a new virus (see Fig. 1). It may be pro-
posed, therefore, that the apparent rise of HIV prevalence between 1990 and 2000 
UHÁHFWV WKH ULVH RI D QHZ HSLGHPLF RI+,9DQWLERG\ WHVWLQJ+,9WHVWLQJ HSLGHPLFV
ÀUVW VWDUWHG LQ WKH86DIWHU WKHDFFHSWDQFHRI WKHQHZ+,9$,'6K\SRWKHVLV LQ
and then in many other countries of the world (See Introduction). 
In all countries where testing was introduced the prevalence of HIV-antibodies 
was soon found to be steady as it would be expected if HIV were a long-established 
endemic retrovirus (Duesberg, 1996; Duesberg, 1992; Duesberg et al., 2003). In the 
US, for example, 1 million have been HIV-antibody-positive since 1985 (Curran et 
al., 1985; Institute of Medicine, National Academy of Sciences, 1986; Duesberg et al., 
2003; Centers for Disease Control and Prevention, 2007, 2008). In Italy, about 140,000 
– 180,000 have been HIV-antibody-positive since the beginning of testing in the 1980s 
(Ministero della Salute, Italy, 2011; Istituto Superiore di Sanità, Italy, 2007).
Recent evidence estimating that HIV has been in humans since at least the early 
1900s corroborates the hypothesis that HIV is a long-established endemic retrovirus 
(Woodman and Williamson, 2009).
Unexpectedly indirect support to the view that HIV is a passenger appears to 
come from the CDC and WHO, which postulate that HIV causes 27 previously 
known diseases, if antibody against HIV is also present (Centers for Disease Control 
and Prevention, 1992; The Durban Declaration, 2000). Since all of these diseases were 
known prior to the presumed recent origin of HIV (Duesberg, 1988) and continue to 
occur in the absence of HIV (Blattner et al., 1988; Duesberg, 1993, 1996), a logical con-
clusion may be that HIV is not necessary for any one of these diseases. 
The CDC and WHO also report over 30 million of HIV antibody-positive people 
in the US, Europe, Asia, and particularly in Africa, who are AIDS-free (The Durban 
Declaration, 2000; Centers for Disease Control and Prevention, 2007, 2008). Thus HIV 
FDQQRW EH VX΀FLHQW WR FDXVH$,'6 6LQFH+,9 UHSOLFDWHV DQG LQGXFHVYLUXVQHXWUDO-
izing antibodies within weeks after infection (Clark et al., 1991; Daar et al., 1991), it 
should cause AIDS prior to immunity, when it is biochemically active, just like con-
ventional pathogenic viruses (Fenner 1974: Mims & White 1984). Since that is never 
observed, HIV is postulated to depend on exceedingly long latencies of 5-10 years 
DIWHU WKH LQGXFWLRQ RI LPPXQLW\ WR FDXVH$,'6 :HLVV DQG -DͿH  7KH'XUEDQ
Declaration, 2000; Henry et al., 2006). According to this view HIV depends on still 
unknown, time-dependent events to cause AIDS (Duesberg et al., 2003; Henry et al., 
DQGWKXVDSSHDUVWREHLQVX΀FLHQWWRFDXVH$,'6E\LWVHOI
Likewise the CDC reports a steady 1 to 1.5 million of HIV-positive Americans 
since 1985 (see pages 186 and 191 above, and Duesberg et al. 2003).  Since immigra-
tion of HIV-positives is banned, this indicates that the mortality of average Ameri-
can HIV-positives is close to normal. Furthermore, a study of the US Army report-
ed recently that about 5% HIV-positive soldiers (Renzullo et al., 2001) “through an 
experiment of nature” developed no AIDS for up to 20 HIV-antibody-positive years 
ZLWKRXW DQWL+,9 WUHDWPHQWV 2NXOLF] HW DO  FRQÀUPLQJ WKHYLHZ WKDW+,9 LV
QRW VX΀FLHQW IRU$,'67KH UHDVRQ IRU$,'6IUHH+,9 LQIHFWLRQZDVQRW VROYHGE\
the Army’s study. But since the Army’s study did not investigate the use of recre-
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ational drugs, although the majority of American AIDS patients have used recrea-
tional and anti-viral drugs (Duesberg et al., 2003, see also Introduction), it is possible 
that the AIDS-free HIV-positives were those who had used neither recreational nor 
DQWLYLUDO GUXJV 7KH WR[LF HͿHFWV RI DQWLYLUDO GUXJV DUH GHVFULEHG LQ WKH QH[W VHF-
tion. Thus the CDC, the WHO and the US Army provide evidence that supports our 
demographic evidence that HIV is a passenger virus.
6. Can anti-HIV drugs be bene!cial, particularly if HIV is not pathogenic per se?
The evidence that HIV may be not pathogenic casts a new light on the question 
KRZ$,'6VKRXOGEHWUHDWHG,QYLHZRIWKLVZHUHYLHZKHUHEULHÁ\WKHWKHRUHWLFDOOLP-
LWVRIDQWLUHWURYLUDO DQWL+,9WUHDWPHQWVDQGWKHQWKHHͿHFWVRIFXUUHQWO\XVHGDQWL
HIV drugs, particularly those recommended for South Africa (Chigwedere et al., 2008). 
1) Antiviral drugs are inevitably toxic. Owing to their low genetic complexity all virus-
es are obligatory parasites that depend on the host cell for the synthesis of viral DNA, 
RNA and proteins (Crick and Watson, 1956). Viral DNA, RNA and protein synthesis can 
thus only be inhibited via that of the cell. It is for this reason that all antiviral drugs are 
inevitably cytotoxic (see also Duesberg et al., 2003). It is presumably also for this reason 
that even nature has never evolved any antiviral drug – except antiviral immunity. 
Moreover, there are no replicating HIV DNA-, RNA- and protein targets in peo-
ple with antibodies against HIV, because antiviral antibodies inhibit virus replication 
(Clark et al, 1991; Daar et al, 1991; Duesberg, 1988, 1989, 1992, 1994; Duesberg et al., 
2003). The chronic latency of the virus in all antibody-positive people is also the rea-
son why virtually no virus is detectable in AIDS patients and why viral DNA and 
51$DUHRQO\GHWHFWDEOHDIWHUELOOLRQIROGDPSOLÀFDWLRQVZLWK WKHSRO\PHUDVH FKDLQ
reaction in vitro (Duesberg et al., 2003; Rodriguez et al., 2006). Nevertheless this pro-
FHGXUH LVFDOOHG´YLUDO ORDGWHVWµDOWKRXJKLWJHQHUDWHVD´ORDGµRQO\DUWLÀFLDOO\RXW-
side the body, in vitro. This is pointed out here, because the polymerase chain reac-
tion is designed to detect just one or a few HIV DNA or RNA fragments of about 1 
kilobase in HIV-positive people by generating billions of copies of these viral genom-
ic fragments in vitro. Thus this test detects trace fragments of HIV DNA or RNA, far 
below the thresholds of direct pathogenicity, and cannot distinguish between intact 
and defective viruses. In the following we discuss the expected toxicities of anti-HIV 
drugs currently used or recommended for African AIDS.
2) Anti-HIV-AIDS drugs recommended for African AIDS. Based on “modeling” of 
the putative South African HIV-AIDS epidemic described above (Section 2) and on 
´FRQVHQVXVVFLHQWLÀFRSLQLRQµ WKH'1$FKDLQ WHUPLQDWRU$=7DQGWKH'1$LQKLEL-
tor Nevirapine have been recently recommended as anti-HIV-AIDS treatments and 
“prophylaxis” by Chigwedere et al. (2008). 
$=7ZDVGHYHORSHGLQWRWHUPLQDWHKXPDQ'1$V\QWKHVLVIRUFDQFHUFKHPR-
therapy (Horwitz et al., 1964) and is used since 1987 to treat AIDS by inhibiting HIV 
DNA synthesis (Kolata, 1987). As DNA chain-terminator it is inevitably cyto-toxic and 
immuno-toxic, much like most other cancer chemotherapies (Horwitz et al., 1964).
Nevirapine was recently developed to inhibit HIV DNA synthesis, and is rec-
ommended as “prophylaxis” against “mother-to-child transmission” of HIV (Chig-
wedere et al., 2008). In the following we list known toxicities of these drugs.
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7R[LFLWLHVRI$=71HYLUDSLQHDQGRWKHUDQWL+,9$,'6GUXJV,WLVNQRZQVLQFH
the beginnings of anti-HIV-AIDS therapy and “prophylaxis” in 1987 that, “more than 
KDOIRIDOO$,'6SDWLHQWVPD\QRWEHQHÀW IURP WKHGUXJEHFDXVH LW LVPRUH WR[LF IRU
WKHPWKDQWKHLU$,'6LQIHFWLRQµ.RODWD´7KHPRVWVHULRXVVLGHHͿHFWRI$=7
is to suppress the bone marrow leaving patients highly vulnerable to bacterial infec-
WLRQVµ .RODWD6LQFH WKHVDPHHͿHFW LVDOVRDWWULEXWHG WR+,9FRQWUROOHG WHVWV
DUHQHFHVVDU\WRGHWHUPLQHZKHWKHUWKHGUXJLVLQIDFWEHQHÀFLDO
7KHRULJLQDO SODFHERFRQWUROOHG VWXG\RI$=7XQGHUWDNHQ WR WHVW$=7·V DELOLW\
to cure AIDS, showed life-threatening anemia in 24% and neutropenia in 16% within 
several weeks after treatment (Richman et al., 1987). In addition, “serious adverse 
reactions, particularly bone marrow suppression, were observed. Nausea, myalgia, 
insomnia, and severe headaches were reported more frequently by recipients of 
$=7PDFURF\WRVLV GHYHORSHGZLWKLQZHHNV LQPRVW RI WKH$=7 JURXSµ 5LFKPDQ
HW DO 7KLUW\RI $=7 UHFLSLHQWV FRXOGRQO\EHNHSW DOLYHE\EORRG WUDQV-
IXVLRQV )LVFKO HW DO  %\ PRQWKV  RI WKH$=7 JURXS DQG  RI WKH
FRQWUROJURXSZKRE\WKHQKDGDOVRUHFHLYHG$=7RQD´FRPSDVVLRQDWHEDVLVµKDG
died (Fischl et al., 1989).
,QWKHDELOLW\RI$=7WRSUHYHQW$,'6ZDVWHVWHGE\WKH%ULWLVK)UHQFK&RQ-
corde study, the largest, placebo-controlled study of its kind (Aboulker and Swart, 
1993; Seligmann et al., 1994). This study investigated the onset of AIDS and death 
of 1749 HIV-positive, mostly male homosexual subjects, which had been divided into 
DQXQWUHDWHGDQGDQ$=7WUHDWHGVXEJURXS ,WZDVIRXQGWKDW$=7LVXQDEOH WRSUH-
vent AIDS and increases the mortality by 25%. In view of this it was concluded, “The 
UHVXOWVRI&RQFRUGHGRQRWHQFRXUDJHWKHHDUO\XVHRI]LGRYXGLQH$=7LQV\PSWRP
free HIV-infected adults.” (Seligmann et al., 1994).
More recent studies also demonstrate that up to half of all HIV–positive Ameri-
FDQ$,'6SDWLHQWVWUHDWHGZLWKDQWLYLUDOGUXJFRFNWDLOVLQFOXGLQJ$=7GLHIURP+,9
LQGHSHQGHQWQRQ$,'6GHÀQLQJGLVHDVHV)RUH[DPSOH5HLVOHUHWDOREVHUYHG´7KH
most common grade 4 events [“serious or life-threatening events that are not AIDS 
GHÀQLQJµ@ZHUH OLYHUUHODWHGSDWLHQWVSHUSHUVRQ\HDUV&DUGLRYDVFXODU
events were associated with the greatest risk of death (hazard ratio = 8.64; 95% CI: 5.1 
WR7KHÀUVWJUDGHHYHQWDQG WKHÀUVW$,'6HYHQWZHUHDVVRFLDWHGZLWKVLPL-
lar risks of death, 5.68 and 6.95, respectively.” (Reisler et al., 2003). Likewise, a study 
of antiretroviral treatments found that “an important secondary end point was major 
cardiovascular, renal, or hepatic disease.” (El-Sadr et al., 2006). A Danish group also 
concluded recently after studying the causes of death among AIDS patients treated 
with anti-viral drugs, “Almost half of deaths in persons diagnosed with HIV in a 
health care setting with free access to highly active antiretroviral therapy stemmed 
from factors unrelated to HIV disease.” (Lohse et al. , 2011).
2WKHU UDUH SXEOLFDWLRQV VKRZ$,'6GHÀQLQJZDVWLQJGLVHDVH HYHQ LQ+,9QHJD-
tive adults treated erroneously with anti-HIV drugs (Guthrie J., newspaper article on 
“False diagnosis of HIV discovered after 8 years” in the San Francisco Chronicle, San 
Francisco pp. B1, B7, August 27, 2004). According to the responsible physician, “the 
patient exhibited symptoms that could be consistent with an HIV diagnosis”. 
1XPHURXVFOLQLFDOREVHUYHUVKDYHFRUURERUDWHGWKHVHÀQGLQJVRYHUWKH\HDUV)RU
example, AIDS researchers at the International AIDS conference in Vienna in 2010 
´UHDVVXUH>G@ FOLQLFLDQV RI QRW VWDUWLQJ >DQWLUHWURYLUDO WKHUDS\@$57 ZKHQ SDWLHQWV
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report a stable CD4” in agreement with the Concorde study. Likewise, the State of 
&DOLIRUQLDKDV MXVWZDUQHGDERXWWKH LQKHUHQWWR[LFLW\RI$=7DVFDUFLQRJHQDQGSDU-
ticularly as toxin for embryonic development (California State, 2011), which should 
be of special concern to embryologists. And a recent Italian study reported that the 
high toxicity of early anti-HIV treatment was responsible for the death of 2000 AIDS 
patients in 1997 (Ruggiero et al., 2009).
Regarding Nevirapine, recommended as possible prophylaxis of mother-to-child 
transmission of HIV (Chigwedere et al., 2008), the National Institutes of Health (NIH) 
Treatment Guidelines advise that the drug may induce ‘‘liver failure and severe skin 
reactions” in addition to ‘‘rush, headaches, diarrhea, fever, abdominal pain and myal-
JLDµ )XUWKHU WKH JXLGHOLQHV SRLQW RXW WKDW ¶¶WKH ULVN RI VHYHUDO QRQ$,'6GHÀQLQJ
conditions, including cardiovascular diseases, liver-related events, renal disease, and 
certain non-AIDS malignancies is greater than the risk for AIDS in persons with CD4 
T-cell counts >200 cells/mm3”.
$PDJD]LQHDUWLFOHSXEOLVKHG LQRͿHUHGUDUHYLHZVRI WKHYDULRXVDEQRUPDO
facial and bodily appearances of nine HIV-positive Americans treated with anti-HIV 
GUXJFRFNWDLOVVXFKDVDFFHOHUDWHGDJLQJDQGGLVÀJXUDWLRQVZKLFKDUH WHUPHG´VHUL-
RXVDGYHUVHHͿHFWVµ )UDQFH'QHZVSDSHUDUWLFOHRQ´$QRWKHU.LQGRI$,'6&ULVLV
A striking number of HIV patients are living longer but getting older faster—show-
ing early signs of dementia and bone weakness usually seen in the elderly” in New 
York Magazine, New York, November 1, 2009). By contrast, such appearances are not 
observed in the estimated 34 million mostly untreated, asymptomatic HIV antibody-
positives (The Durban Declaration, 2000). A recent British-American collaborative 
VWXG\KDV VLQFH FRQÀUPHG´WKDWSHRSOHZLWK VXFFHVVIXOO\ WUHDWHG+,9 LQIHFWLRQDJH
prematurely, leading to progressive multi-organ disease,” in part because “patients 
treated with commonly used nucleoside analog anti-retroviral drugs progressively 
accumulate somatic mitochondrial DNA mutations, mirroring those seen much later 
in life caused by normal aging.” (Payne et al., 2011).
Furthermore treatment of unborn or newborn babies, which the Harvard study 
recommends, shows that anti-HIV drugs cause various forms of genetic damage 
including also ‘‘long-term mitochondrial toxicity” (Poirier et al., 2003), ‘‘persistent 
mitochondrial dysfunction” (Barrett et al., 2003), in addition to ‘‘chromosome loss 
and duplication, somatic recombination and gene conversion”, which ‘‘justify surveil-
lance for long-term genotoxic (mutagenic) consequences” (Escobar et al., 2007). This 
VKRXOG SURPSW IXUWKHU LQYHVWLJDWLRQV WR JLYH D VRXQG EDVLV WR WKH ULVNDQGEHQHÀW
balance evaluation in prenatal and early postnatal life. These genetic defects are treat-
ment-dependent and HIV-independent, because the same defects were found in HIV-
negative children of HIV-positive mothers treated with anti-HIV drugs (Duesberg 
et al., 2003; Poirier et al., 2003; Brogly et al., 2007). Another rare study describes an 
HIV-free baby, who had developed Pneumocystis pneumonia after prophylactic treat-
ments with antiviral drugs, because the mother was HIV-positive (Heresi et al., 1997). 
Independent, rarely mentioned animal experiments with mice, rats, dogs and 
PRQNH\V KDYH DOVR VKRZQ WKDW DQWL+,9 GUXJV FDXVH LPPXQRGHÀFLHQF\ DQHPLD
muscle atrophy, nephropathy, liver disease, cancer of lung, liver and vagina, and 
deaths, as well as retarded development and abortions; as far as developing organ-
isms are concerned, it is relevant that these drugs may cause the same diseases and 
outcomes in humans (reviewed in Duesberg et al., 2003). 
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:H GHGXFH IURP WKHVH ÀQGLQJV WKDW DQWL+,9 GUXJV DUH LQHYLWDEO\ WR[LF FDQ
LQGXFH$,'6GHÀQLQJDQGQRQ$,'6GHÀQLQJGLVHDVHV:HGRQRW UXOHRXWKRZHY-
HU WKDWDQWL+,9GUXJVRZLQJWR WKHLU LQKHUHQWF\WRWR[LFHͿHFWVFDQKDYHEHQHÀFLDO
HͿHFWVDJDLQVW´RSSRUWXQLVWLFµPLFURELDOGLVHDVHVDQGFDQFHUV LISUHVFULEHG IRU OLP-
ited periods of time (Duesberg et al., 2003; Monini et al., 2004). In agreement with us 
DUHFHQWVWXG\LQ1DWXUH*HQHWLFVZDUQHGDERXWWKH´LUUHYHUVLEOHORQJWHUPHͿHFWVRI
the drugs”, which “raise the specter of progressive iatrogenic mitochondrial genetic 
disease emerging over the next decade” (Payne et al., 2011). Other voices have also 
called for caution on when and how to start treatments of asymptomatic HIV-posi-
tive subjects, which might enlarge the reader’s perspective on this point (DART Trial 
Team 2010; Sturt et al., 2010; Nunes et al., 2011; Panel de expertos de Gesida y Plan 
Nacional sobre el Sida, 2011; Siegfried et al., 2011).
7. General Conclusions
In sum, our analyses of African HIV- and AIDS prevalence revealed unexpected 
discrepancies between the reported epidemics of AIDS and of HIV. The predicted epi-
demiological pattern of mortality associated with the putative new AIDS virus nev-
er showed up in South Africa or anywhere else in Africa between 2000 and 2005. On 
the contrary, the African population doubled during the HIV-AIDS era, despite high 
SUHYDOHQFHRI+,92XUÀQGLQJV WKDW WKHUH LVQRHYLGHQFH IRU DQHZ IDWDO+,9$,'6
epidemic in Africa have thus resolved the paradox that HIV would cause a general 
AIDS epidemic in Africa, but not in the rest of the world – namely by the absence of 
said epidemic. 
In view of this and the inherent toxicities of anti-HIV drugs reviewed by us here, 
we propose a reevaluation of the HIV-AIDS hypothesis and of the prescription of 
DQWLYLUDOGUXJV WR+,9DQWLERG\SRVLWLYH VXEMHFWV8QWLO WKHUH LVYHULÀDEOHHYLGHQFH
that HIV is fatally pathogenic, we deduce that South Africa’s ‘‘failure to accept the 
XVHRIDYDLODEOH$59V>DQWL+,9GUXJV@µ&KLJZHGHUHHWDOKDVSUREDEO\VDYHG
rather than cost South African lives.
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Note added in proof
After this manuscript went to press, Apostolova, Blas-Garcia and Esplugues have 
UHYLHZHG ´WKH ORQJWHUP DGYHUVH HͿHFWVµ RI DQWL+,9GUXJV LQFOXGLQJ WKRVH RI WKH
non-nucleoside reverse transcriptase inhibitors such as Nevirapine.  They found that 
WKHVHGUXJVFDXVH´UDVKDQGK\SHUVHQVLELOLW\UHDFWLRQVKHSDWRWR[LFLW\PHWDEROLFGLV-
WXUEDQFHV LQFOXGLQJ OLSRG\VWURSK\ SDQFUHDWLWLV JDVWURLQWHVWLQDO WR[LFLW\ K\SHUODF-
tatemia, hyperlipedimia, insulin resistance, and neuropsychiatric symptoms” (Blas-
*DUFLDHWDO$SRVWRORYDHWDO 7KHVHQHZÀQGLQJVFRQÀUPDQGH[WHQG
reservations we have made here on similar grounds.  Further we draw the attention 
RI WKHUHDGHU WR´7KH0\WKRI+HWHURVH[XDO$,'6µE\)XPHQWRDV LQGHSHQGHQWHYL-
dence for the absence of a general AIDS epidemic in the US (Fumento, M, 1990).
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